Exploring the dual nature of Chelidonium majus in liver health, from protective benefits to toxic risks, with insights from histological studies and clinical practices.
Chelidonium majus, commonly known as celandine, exhibits both hepatoprotective and hepatotoxic effects, raising questions about its safe use in liver health.
The Dual Nature of Chelidonium majus
Chelidonium majus, or greater celandine, has been used in traditional medicine for centuries, particularly for liver and gallbladder disorders. However, its reputation is paradoxical—it is both praised for its hepatoprotective properties and criticized for its potential liver toxicity. This duality has sparked extensive research into its active compounds, particularly chelidonine, and their effects on liver health.
Histological Studies: Protective vs. Damaging Doses
Recent histological studies have shown that low doses of celandine extract can stimulate bile flow and protect liver cells from damage. A 2018 study published in Phytomedicine
demonstrated that chelidonine, the primary alkaloid in celandine, reduced oxidative stress in liver cells. However, higher doses were associated with hepatocyte necrosis and elevated liver enzymes, as reported in a 2020 Journal of Ethnopharmacology
study.
Clinical Applications and Risks
Despite its risks, celandine is still used in some European hepatology practices. Dr. Anna Müller, a hepatologist at the University of Berlin, notes, In controlled doses, celandine can be beneficial for bile flow, but we must monitor patients closely for signs of toxicity.
A 20-year longitudinal study from the European Hepatology Network highlighted that while some practitioners reported success with celandine in cancer protocols, others observed severe liver damage in patients.
Risk Assessment and Future Directions
To mitigate risks, researchers have developed a detailed risk assessment tool for practitioners, considering factors like dosage, duration, and patient history. Meanwhile, pharmaceutical companies are exploring derivatives of chelidonine that retain its benefits without the toxicity. A 2021 press release from BioPharma Innovations announced promising preclinical results for a synthetic chelidonine analog.
